Dimitrios Basoulis
Overview
Explore the profile of Dimitrios Basoulis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
421
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maltezou H, Gamaletsou M, Chini M, Petrakis V, Rapti V, Giannouchos T, et al.
Infect Med (Beijing)
. 2024 Dec;
3(4):100144.
PMID: 39624059
Background: To estimate the protection that coronavirus disease 2019 (COVID-19) vaccine doses conferred to hospitalized patients with COVID-19 against adverse outcomes and longer length of stay during the Omicron BA.2...
2.
Roussos S, Pantazis N, Protopapas K, Antoniadou A, Papadopoulos A, Lourida G, et al.
Euro Surveill
. 2024 Nov;
29(48).
PMID: 39611208
BackgroundLate HIV diagnosis (CD4+ T-cell count < 350 cells/μL, or with an AIDS-defining event) remains a persistent challenge in Greece, indicating potential missed opportunities (MOs) for earlier testing.AimTo determine the...
3.
Basoulis D, Mastrogianni E, Karamanakos G, Gkoufa A, Georgakopoulou V, Makrodimitri S, et al.
Viruses
. 2024 Aug;
16(8).
PMID: 39205319
Background: COVID-19 continues to pose a threat to immunocompromised individuals, even with vaccination. The monoclonal antibodies (mAbs) tixagevimab/cilgavimab (TXG/CIL) provide targeted prophylaxis against SARS-CoV-2 with the benefit of a prolonged...
4.
Thomadakis C, Basoulis D, Tsachouridou O, Protopapas K, Paparizos V, Astriti M, et al.
Viruses
. 2024 Jun;
16(6).
PMID: 38932178
People living with HIV-HCV co-infection comprise a target group for HCV-micro-elimination. We conducted an HCV cascade of care (CoC) for HIV-HCV co-infected individuals living in Greece and investigated factors associated...
5.
Tentolouris N, Achilla C, Anastasiou I, Eleftheriadou I, Tentolouris A, Basoulis D, et al.
Nutrients
. 2024 Mar;
16(5).
PMID: 38474855
Background: Association studies of vitamin D receptor (VDR) polymorphisms with COVID-19 severity have produced inconsistent results in different populations. Herein we examined gene polymorphisms in a Caucasian Greek cohort of...
6.
Nitsotolis T, Kyriakoulis K, Kollias A, Papalexandrou A, Kalampoka H, Mastrogianni E, et al.
Medicina (Kaunas)
. 2024 Feb;
60(2).
PMID: 38399618
The success of combined antiretroviral therapy (cART) has led to a dramatic improvement in the life expectancy of people living with HIV (PLWH). However, there has been an observed increase...
7.
Georgakopoulou V, Gkoufa A, Makrodimitri S, Tsakanikas A, Basoulis D, Voutsinas P, et al.
Exp Ther Med
. 2023 Dec;
27(1):22.
PMID: 38125348
Coronavirus disease 2019 (COVID-19) is characterized by poor outcomes and a high mortality rate, particularly among elderly patients. Since the beginning of the pandemic, an older age has been recognized...
8.
Kapetanakis A, Karakatsoulis G, Kyrou D, Ntourou I, Vrontaras N, Tsachouridou O, et al.
PLoS One
. 2023 Nov;
18(11):e0292787.
PMID: 37983204
Objective: Despite the significant advances in healthcare, people living with HIV still face challenges that affect their quality of life (QoL), both in terms of their physical state as represented...
9.
Georgakopoulou V, Gkoufa A, Makrodimitri S, Basoulis D, Tsakanikas A, Karamanakos G, et al.
Exp Ther Med
. 2023 Sep;
26(4):462.
PMID: 37664680
Remdesivir, a viral RNA polymerase inhibitor, has constituted a key component of therapeutic regimens against the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Originally approved for administration in...
10.
Basoulis D, Tsakanikas A, Gkoufa A, Bitsani A, Karamanakos G, Mastrogianni E, et al.
Viruses
. 2023 Jul;
15(7).
PMID: 37515201
Background: Nirmatrelvir/ritonavir (NMV/r) and three-day course remdesivir (3RDV) have been approved as early treatments for COVID-19 outpatients not requiring supplemental oxygen. Real-life data on the efficacy of antivirals among immunocompromised...